Treatment of functional dyspepsia

被引:15
作者
Delgado-Aros S. [1 ]
Cremonini F. [1 ]
Talley N.J. [1 ]
机构
[1] Clin Enteric Neurosci. Translational, Epidemiological Research Program, Mayo Clinic, Rochester, MN 55905
关键词
Irritable Bowel Syndrome; Dyspepsia; Misoprostol; Cisapride; Functional Dyspepsia;
D O I
10.1007/s11938-004-0033-1
中图分类号
学科分类号
摘要
Functional dyspepsia is a common chronic condition. It can have a major impact on quality of life and remains a large burden on healthcare resources. Its underlying mechanisms are not fully understood and therapies are mainly empirical. In this review, we summarize the best evidence on available therapeutic interventions in functional dyspepsia. Helicobacter pylori eradication, for those infected, is likely a safe and cost-effective strategy but benefits only a minority. Antisecretory agents such as proton-pump inhibitors and histamine-2 receptor antagonists have shown some benefit and are recommended as the first-line option in the absence of H. pylori infection. There is a lack of strong evidence of benefit from prokinetic agents, and cisapride, the most studied agent, is largely unavailable. Antidepressants need to be adequately tested in functional dyspepsia, but both psychotherapy and hypnotherapy interventions have shown promising results. Herbal therapies need further study in these patients. 5-Hydroxytryptamine3 (5-HT3) and 5-HT4 receptor antagonists, and cholecystokinin type A and neurokinin receptor antagonists remain promising emerging therapies. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:121 / 131
页数:10
相关论文
共 53 条
[1]  
Talley N.J., Stanghellini V., Heading R.C., Et al., Functional gastroduodenal disorders, Gut, 45, SUPPL. 2, pp. 37-42, (1999)
[2]  
Kay L., Jorgensen T., Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors, Scand. J. Gastroenterol., 29, pp. 2-6, (1994)
[3]  
Frank L., Kleinman L., Ganoczy D., Et al., Upper gastrointestinal symptoms in North America: Prevalence and relationship to healthcare utilization and quality of life, Dig. Dis. Sci., 45, pp. 809-818, (2000)
[4]  
Marsland D.W., Wood M., Mayo F., Content of family practice. Part I. Rank order of diagnoses by frequency. Part II. Diagnoses by disease category and age/sex distribution, J. Fam. Pract., 3, pp. 37-68, (1976)
[5]  
Nyren O., Adami H.O., Gustavsson S., Et al., Social and economic effects of non-ulcer dyspepsia, Scand. J. Gastroenterol., 109, SUPPL., pp. 41-47, (1985)
[6]  
Talley N.J., Silverstein M.D., Agreus L., Et al., AGA technical review: Evaluation of dyspepsia, Gastroenterology, 114, pp. 582-595, (1998)
[7]  
Veldhuyzen van Zanten S.J., Flook N., Chiba N., Et al., An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori, Can. Med. Assoc. J., 162, SUPPL. 12, (2000)
[8]  
Rauws E.A., Tytgat G.N., Cure of duodenal ulcer associated with eradication of Helicobacter pylori, Lancet, 335, pp. 1233-1235, (1990)
[9]  
Laine L., Schoenfeld P., Fennerty M.B., Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials, Ann. Intern. Med., 134, pp. 361-369, (2001)
[10]  
Moayyedi P., Soo S., Deeks J., Et al., Eradication of Helicobacter pylori for non-ulcer dyspepsia, Cochrane Database Syst. Rev., 1, (2003)